Golimumab

Brand: Simponi / Golimumax

Immunomodulator TNF-alpha monoclonal antibody (IgG1κ)

Chemistry

PubChem

CID: 16127541
Open in PubChem

Structure

Half-life	14 days
Clearance Route	reticuloendothelial
Active Metabolites	none
Notes	Given SC or IV. Fully human monoclonal antibody → lower immunogenicity. Infection risk similar to other TNF blockers.

Severity: Severe

Adverse Effects:
Serious infections (TB, fungal), injection reactions, hepatotoxicity, demyelinating disease, CHF exacerbation

Contraindications:
Active infections, untreated TB, moderate–severe heart failure

Precautions:
TB & HBV screening mandatory; avoid live vaccines; monitor LFTs; caution in demyelinating disease